AMPH-1 As A Critical Tumor Suppressor That Inhibits Osteosarcoma Progression
Authors Zhang H, Liu Y, Xu K, Mao K, Han W, Xu F, Wan W, Sun Y
Received 24 June 2019
Accepted for publication 22 October 2019
Published 25 November 2019 Volume 2019:11 Pages 9913—9919
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Ahmet Emre Eskazan
Haiyun Zhang,1,* Yujie Liu,2,* Kehan Xu,2,* Kai Mao,1 Weidong Han,1 Feifan Xu,1 Wei Wan,2 Yajun Sun3
1Department of Laboratory Medicine, The Sixth People’s Hospital of Nantong, Jiangsu 226000, People’s Republic of China; 2Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, People’s Republic of China; 3Department of Laboratory Medicine, The Fourth People’s Hospital of Nantong, Jiangsu 226000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yajun Sun; Wei Wan
Department of Laboratory Medicine, The Fourth People’s Hospital of Nantong, Chenggang Road, Jiangsu 226000, People’s Republic of China
Email firstname.lastname@example.org; email@example.com
Introduction: Amphiphysin 1 (AMPH-1) is involved in endocytosis, and its expression is upregulated in osteosarcoma compared with osteofibrous dysplasia.
Methods: We investigated the role of AMPH-1 in osteosarcoma cells via both gain-of-function and loss-of-function experiments.
Results: Knockdown of AMPH-1 in osteosarcoma cells promoted cell cycle progression and cell proliferation and attenuated apoptosis. Notably, silencing AMPH-1 increased osteosarcoma progression in a mouse tumor model. The results obtained upon AMPH-1 knockdown and AMPH-1 overexpression indicates that AMPH-1 is involved in regulating MEK/ERK signaling.
Conclusion: These data suggest that AMPH-1 plays an important role in osteosarcoma and may represent a novel therapeutic target for osteosarcoma treatment.
Keywords: AMPH-1, osteosarcoma, ERK signaling pathway
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]